Series A · Biotech
RegCell raises $44M Series A to advance autoimmune cell therapy
The platform is designed to avoid gene engineering and broad immunosuppression.
Reprogramming the immune response
RegCell converts pathogenic conventional T cells into stable regulatory T cells that can suppress autoimmune activity. The company is developing the epigenetic approach for conditions including myasthenia gravis, rheumatoid arthritis, ulcerative colitis and autoimmune liver disease, with plans to move the platform toward clinical-stage development and expand proof-of-concept work.
Use of funds
Advance epigenetic reprogramming into clinical development
Expand clinical pipeline and Phase 2 studies
Accelerate second-generation platform
Funding history
Series A · This round$44M